{"title": "Modelling the epidemic trend of the 2019-nCOV outbreak in Hubei Province, China", "doi": "10.1101/2020.01.30.20019828", "citation_id": "2020.01.30.20019828v2", "date": "2020-02-06", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.01.30.20019828", "abstract": "<p>As of 8am 30th January (Beijing Time) 2020, Approximate 8000 cases across the world have been confirmed. It9s necessary to simulate epidemic trend of the 2019-nCOV outbreak in Hubei Province, the hardest-hit area. By SEIR simulation, the predicted epidemic peak in Hubei will be within 28th January 2020 to 7th February 2020, up to 7000-9000 infectious cases in total. The estimate above was based on some assumptions and limitations exited.</p>", "twitter_description": "As of 8am 30th January (Beijing Time) 2020, Approximate 8000 cases across the world have been confirmed. It's necessary to simulate epidemic trend of the 2019-nCOV outbreak in Hubei Province, the hardest-hit area. By SEIR simulation, the predicted epidemic peak in Hubei will be within 28th January 2020 to 7th February 2020, up to 7000-9000 infectious cases in total. The estimate above was based on some assumptions and limitations exited.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nno external funding\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nall the data in the manuscript were collected from National Health Commission of the People\u0092s Republic of China and published papers (including preprint)", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.01.30.20019828v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.01.30.20019828v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.01.30.20019828v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/06/2020.01.30.20019828.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.01.30.20019828v2", "access_rights": "restricted", "authors": ["Lizhe Ai"]}